#Novartis to Charge $475,000 for Cancer Treatment US Taxpayers Paid $200 Million to Discover
▻http://thefreethoughtproject.com/novartis-charge-475000-cancer-treatment-us-taxpayers-paid-200
▻http://thefreethoughtproject.com/wp-content/uploads/2017/09/novartis
Novartis announced the price this week of $475,000 per treatment. This was sold to the public as an ostensible win since the drug was predicted to be priced at $600,000 to $750,000 per treatment. If Novartis had solely financed and conducted their own research, of course, they could certainly charge whatever they wanted to charge. But this is not the case, according to the advocacy group Patients for Affordable Drugs.
According to David Mitchell, the founder of the group, $475,000 per treatment is excessive because the federal government threw more than $200 million of your tax dollars into researching CAR-T therapy. According to Mitchell, Novartis simply purchased the rights to the treatment and failed to disclose what amount, if any, they invested in the research.
On Thursday, Mitchell released the following statement praising the FDA’s decision to approve the drug, but decrying the monopoly granted to Novartis.
